In haematological and melanoma cancers reduced levels of 5hmC have been ascribed to loss of TET catalytic function because of mutation, cofactor availability or competitive inhibition by oncometabolites such as 2-hydroxygluterate formed by mutations in isocitrate dehydrogenase (IDH1 and IDH2) enzymes. This evidence concerns the gene IDH2 and cancer.